#depomed

[en24news]

Gabapentin Markt 2020 - Pfizer, Depomed, TEVA, Mylan, Arbor Pharma - NewsVideo24

Gabapentin Markt 2020 – Pfizer, Depomed, TEVA, Mylan, Arbor Pharma – NewsVideo24

[ad_1]

The research study presented in this report provides a complete and intelligent analysis of the competition, segmentation, dynamics and geographic progress of the Gabapentin market, The research study was carried out using in-depth qualitative and quantitative analysis of the gabapentin market. We have also created absolute opportunity and other types of market…

View On WordPress

[worldfinancialdata-blog]

Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain

[moneyhealthfinance-blog]

Depomed Executes an Exit Strategy for Its Opioid Drug

After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is good news for the company because its revenue and profit have been falling this year due to waning demand for Nucynta. Does this deal make Depomed a buy? Exit, stage left Depomed probably wishes it had a…

View On WordPress

[technewsdirectory]

Is activist investor Starboard looking to run at Hewlett Packard Enterprise?

http://dlvr.it/Mfz4rq

[owenpu-blog]

Starboard Sets Sights on Board Seats at DepoMed

[owenpu-blog]

Starboard Sets Sights on Board Seat at DepoMed

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/healthcare-cheap-buy-depomed-nasdaqdepo/13638/

Healthcare Cheap Buy: Depomed (NASDAQ:DEPO)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Depomed, Inc. (NASDAQ:DEPO) [Trend Analysis] a company in the Healthcare industry which traders have been highly interested in of late, to assess if it provides value for investors considering buying or selling it. Currently Depomed, Inc. is trading at $27.65 after moving unchanged 0.00% in the previous day of trading.

DEPO is trading with a trailing 12 month P/E multiple of 14.94 and an estimated forward P/E multiple of 20.68. The stock has an estimated 5 year annual growth of 29.88% and a PEG multiple of 0.50.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Depomed, Inc. is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of DEPO. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of DEPO being 0.50, we consider Depomed, Inc. to likely be underpriced.

This analysis means that value buyers who do not currently hold Depomed, Inc. (NASDAQ:DEPO) should consider buying and investors currently holding the stock should continue holding.

The mean analyst 12 month target price for Depomed, Inc. (NASDAQ:DEPO) is currently $27.92 or 0.99% above the current price. Additionally, the stock has been as high as $27.87 and as low as $9.85 in the last 52 weeks. Analysts are estimating that DEPO will report earnings per share of $0.17 next quarter.

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/value-buy-depomed-inc-nasdaqdepo/10840/

Growth Buy: Depomed (NASDAQ:DEPO)

(adsbygoogle = window.adsbygoogle || []).push();

We perform a growth and value analysis on the fundamentals of Depomed, Inc. (NASDAQ:DEPO) [Trend Analysis] and determine that although the stock looks over priced when looking at the forward earnings one period ahead, from a growth perspective into the future the stock is underpriced and could certainly be a good investment for longer term focused buyers.

Depomed, Inc. (NASDAQ:DEPO) last traded at $23.06 after moving up 5.06% for the trading day.

DEPO is trading with a trailing 12 month P/E multiple of 12.46 and an estimated forward P/E multiple of 25.71. The stock has an estimated 5 year annual growth of 29.67% and a PEG multiple of 0.42.

From a value investor perspective, as mentioned Depomed, Inc. trades on an estimated forward P/E multiple of 25.71. The current estimated forward P/E ratio for the market as a whole is approximately 19.00. Therefore, for value investors DEPO appears to be overpriced.

For growth investors, who are more interested in growth into the longer term for the stock, we look at the PEG multiple (P/E to growth) of Depomed, Inc. (NASDAQ:DEPO). This PEG multiple takes into account the expected long term growth in earnings of Depomed, Inc. rather than merely the growth for one full earnings period ahead.

As a rule of thumb, growth investors often believe a stock with a PEG of between 0 and 1 is considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of DEPO being 0.42, we consider Depomed, Inc. to likely be underpriced.

The mean analyst 12 month target price for Depomed, Inc. (NASDAQ:DEPO) is currently $23.40 or 1.47% above the current price. Additionally, the stock has been as high as $23.20 and as low as $9.85 in the last 52 weeks. Analysts are estimating that DEPO will report earnings per share of $0.06 next quarter.